Case report: Tirzepatide for mitochondrial diabetes mellitus with a mutation at position 3271 and transient GAD antibody positivity

Mitochondrial diabetes mellitus (MDM) is a rare form of diabetes caused by mutations in mitochondrial DNA. MDM is associated with other comorbidities, such as GAD antibody positivity [ [1] Suzuki Y. Taniyama M. Shimada A. Atsumi Y. Matsuoka K. Oka Y. GAD antibody in mitochondrial diabetes associated with tRNA(UUR) mutation at position 3271. Diabetes Care. 2002; 25: 1097-1098 Crossref PubMed Scopus (9) Google Scholar ]. Tirzepatide is a dual GLP-1 and GIP receptor agonist that is effective in treating type 2 diabetes. Tirzepatide has also an effect on type 2 diabetes patients with GAD antibody positivity [ [2] Buzzetti Raffaella, Peters Anne L, Lee Glare J, Pavo Imre, Liu Minzhi, Paik Jim S. Effect of tirzepatide in GADA-positive individuals with type 2 diabetes: a post hoc analysis of the SURPASS 2-5 trials. European Association for the Study of Diabetes 2023; 2023:P-620. Google Scholar ].